Department of Dermatology, Kansai Medical University, Hirakata, Japan.
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Allergol Int. 2023 Jul;72(3):385-393. doi: 10.1016/j.alit.2023.02.005. Epub 2023 Mar 10.
Cryopyrin-associated periodic syndromes (CAPS) and Schnitzler syndrome (SchS) are autoinflammatory diseases that present with urticaria-like rashes. CAPS is characterized by periodic or persistent systemic inflammation caused by the dysfunction of the NLRP3 gene. With the advent of IL-1-targeted therapies, the prognosis of CAPS has improved remarkably. SchS is considered an acquired form of autoinflammatory syndrome. Patients with SchS are adults of relatively older age. The pathogenesis of SchS remains unknown and is not associated with the NLRP3 gene. Previously, the p.L265P mutation in the MYD88 gene, which is frequently detected in Waldenström macroglobulinemia (WM) with IgM gammopathy, was identified in several cases of SchS. However, because persistent fever and fatigue are symptoms of WM that require therapeutic intervention, it is a challenge to determine whether these patients truly had SchS or whether advanced WM was misidentified as SchS. There are no established treatments for SchS. The treatment algorithm proposed with the diagnostic criteria is to use colchicine as first-line treatment, and systemic administration of steroids is not recommended due to concerns about side effects. In difficult-to-treat cases, treatment targeting IL-1 is recommended. If targeted IL-1 treatment does not improve symptoms, the diagnosis should be reconsidered. We hope that the efficacy of IL-1 therapy in clinical practice will serve as a stepping stone to elucidate the pathogenesis of SchS, focusing on its similarities and differences from CAPS.
Cryopyrin 相关周期性综合征 (CAPS) 和 Schnitzler 综合征 (SchS) 均为伴有荨麻疹样皮疹的自身炎症性疾病。CAPS 的特征为 NLRP3 基因突变导致周期性或持续性全身炎症。随着 IL-1 靶向治疗的出现,CAPS 的预后显著改善。SchS 被认为是获得性自身炎症综合征。SchS 患者为年龄较大的成年人。SchS 的发病机制尚不清楚,与 NLRP3 基因无关。先前,在伴有 IgM 球蛋白血症的 Waldenström 巨球蛋白血症 (WM) 中经常检测到的 MYD88 基因 p.L265P 突变,在几例 SchS 中被发现。然而,由于持续性发热和疲劳是需要治疗干预的 WM 症状,因此难以确定这些患者是否真正患有 SchS,还是将进展期 WM 误诊为 SchS。目前尚无针对 SchS 的既定治疗方法。根据诊断标准提出的治疗方案是使用秋水仙碱作为一线治疗药物,由于担心副作用,不建议全身性使用类固醇。在难以治疗的病例中,建议采用靶向 IL-1 的治疗方法。如果靶向 IL-1 治疗不能改善症状,则应重新考虑诊断。我们希望 IL-1 治疗在临床实践中的疗效能够成为阐明 SchS 发病机制的垫脚石,重点关注其与 CAPS 的异同。